LRMR Stock Summary and Trading Ideas (Larimar Therapeutics | NASDAQ:LRMR)

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Larimar Therapeutics trades on the NASDAQ stock market under the symbol LRMR.

As of May 1, 2026, LRMR stock price declined to $3.94 with 2,076,647 million shares trading.

LRMR has a beta of 2.33, meaning it tends to be more sensitive to market movements. LRMR has a correlation of 0.11 to the broad based SPY ETF.

LRMR has a market cap of $409.30 million. This is considered a Small Cap stock.

In the last 3 years, LRMR traded as high as $13.68 and as low as $1.61.

The top ETF exchange traded funds that LRMR belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWN.

LRMR has outperformed the market in the last year with a return of +37.8%, while the SPY ETF gained +30.4%. In the last 3 month period, LRMR beat the market returning +11.3%, while SPY returned +4.4%. However, in the most recent 2 weeks LRMR has underperformed the stock market by returning -17.9%, while SPY returned +1.5%.

LRMR support price is $3.91 and resistance is $4.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LRMR shares will trade within this expected range on the day.